China SXT Pharmaceuticals Return on Equity

China SXT Pharmaceuticals posts a ROE of -24.82%. That is below the Consumer Discretionary sector average of 23.04%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Consumer Discretionary stocks, a ROE near 23.04% is typical. China SXT Pharmaceuticals's -24.82% is lower that level. That is roughly 207.7% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

China SXT Pharmaceuticals's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -24.82%; use YoY and peer views to separate noise from signal.

Context for SXTC's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 23.04%), and (3) consistency with growth and profitability. This page covers the first two; China SXT Pharmaceuticals's other metric pages and overview cover the third.

Judging China SXT Pharmaceuticals against Consumer Discretionary peers is usually better than using a market-wide rule of thumb. Business models inside Consumer Discretionary are more comparable, which makes gaps in ROE easier to interpret. Start with -24.82% here, then scan peer and history charts to see if the gap is persistent.